IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy

Immunotherapy has become the major treatment for tumors in clinical practice, but some intractable problems such as the low response rate and high rates of immune-related adverse events still hinder the progress of tumor immunotherapy. Hence, it is essential to explore additional immunotherapy treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Xi-Yang, Xiong, Yan-Lu, Shi, Xian-Gui, Zhao, Ya-Bo, Shi, An-Ping, Zheng, Kai-Fu, Liu, Yu-Jian, Jiang, Tao, Ma, Nan, Zhao, Jin-Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277907/
https://www.ncbi.nlm.nih.gov/pubmed/35831836
http://dx.doi.org/10.1186/s40364-022-00394-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277907/
https://www.ncbi.nlm.nih.gov/pubmed/35831836
http://dx.doi.org/10.1186/s40364-022-00394-0

Ejemplares similares